Clinical trials
Refractory Acute Myeloid Leukemia clinical trials
Below are recruiting refractory acute myeloid leukemia clinical trials, each written for real people, not researchers. We’re tracking 234 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07565220RecruitingPhase 1
Thiotepa-based stem cell transplant for blood cancers
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06741722RecruitingPhase 2
Study of mitoxantrone liposome combo for relapsed or refractory AML
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
BeijingAges 18–75 - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT06762132RecruitingEarly Phase 1
CD33 car-t cell therapy for returning or hard-to-treat aml
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
Hangzhou, ZhejiangAges 18 years+ - NCT07500753Recruiting
Study of a conditioning regimen for older adults with hard-to-treat leukemia or MDS
This trial tests a chemotherapy combination (Clad-LABU) to prepare older patients for a stem cell transplant. It is for people aged 50 or older with relapsed or refractory AML or high-risk MDS.
Suzhou, JiangsuAges 50 years+ - NCT07471789RecruitingPhase 1/Phase 2
CART84 therapy for AML and T-ALL leukemia
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
Barcelona, BarcelonaAges 18 years+ - NCT07464951RecruitingPhase 1
CART123 cells with or without ruxolitinib for AML
This trial tests a new type of immune cell therapy (CART123) alone or with a drug called ruxolitinib for children and young adults with AML that has come back or not responded to standard treatment. The goal is to see if this combination can help destroy leukemia cells.
Philadelphia, PennsylvaniaAges birth–29 years - NCT07439211RecruitingPhase 1
Testing a new drug combo for acute myeloid leukemia
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
Boston, MassachusettsAges 18–90 - NCT07384715RecruitingPhase 1
GEN3018 for AML or high-risk MDS
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
AarhusAges 18 years+ - NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 12 years+ - NCT07347418RecruitingPhase 1
CD64 CAR T cell therapy for relapsed or refractory AML
This trial tests a type of immunotherapy called CAR T cells that target a protein called CD64 on leukemia cells. It is for adults with AML that has come back or not responded to treatment, including venetoclax.
Aurora, ColoradoAges 18 years+ - NCT05190471RecruitingPhase 1
Study drug for adults with AML that did not respond or returned
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
La Jolla, CaliforniaAges 18 years+ - NCT06201247RecruitingEarly Phase 1
CD123-targeted immune cell therapy for relapsed/refractory AML
This early-phase trial tests an 'off-the-shelf' immune cell treatment (CAR-NK cells) that targets a protein called CD123 on leukemia cells. It's for people with AML that has returned or hasn't responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07306832RecruitingPhase 1
Study of IV Pivekimab Sunirine for Children with Relapsed AML
This study tests an experimental IV drug called pivekimab sunirine for children whose acute myeloid leukemia (AML) has returned or not responded to previous treatments. The drug targets a specific marker on leukemia cells (CD123) to try to kill them.
Palo Alto, CaliforniaAges 6 months–17 years - NCT07303660RecruitingPhase 1
Study of Lonitoclax and azacitidine for AML
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
Moscow, MoscowAges 18 years+ - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT06879847Recruiting
Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Suzhou, JiangsuAges 14–70 - NCT06022003RecruitingPhase 2
Azacitidine plus gilteritinib for FLT3-mutated AML
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
AmiensAges 18 years+ - NCT07263906RecruitingPhase 1
LILRA6 car-t therapy for resistant or relapsed aml
This early-phase trial tests a new cell therapy (CAR-T) that targets a protein called LILRA6 on leukemia cells. It's designed for people whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT06118788RecruitingPhase 1/Phase 2
BG1805 for relapsed or refractory acute myeloid leukemia
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
Guangzhou, GuangdongAges 18–70 - NCT06297941RecruitingPhase 1
Study of REM-422 for AML or high-risk MDS
This trial tests an experimental oral medication called REM-422 for people with AML (a type of blood cancer) that has not responded to treatment or has come back, or for those with high-risk MDS. The goal is to see if it is safe and effective.
Duarte, CaliforniaAges 18 years+
Hear when a new Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory acute myeloid leukemia?
- Yes. Clin2 currently lists 234 recruiting refractory acute myeloid leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory acute myeloid leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.